Contact Us

Dr Shisong Jiang

Home
Blog Standard
Tag: Dr Shisong Jiang
Company News April 25, 2024 Oxford Vacmedix Comments: 0

Regulatory approval of novel TB diagnostic in China granted to OVM licensee CBI

Regulatory approval of novel TB diagnostic in China granted to Oxford Vacmedix licensee Changzhou Biotech First regulatory approval worldwide for any application of the Recombinant Overlapping Peptide (ROP) technology Oxford, UK – 25th April 2024 Press Release – Regulatory approval granted for novel TB diagnostic Oxford Vacmedix (OVM), the UK-based biopharma company developing vaccines to treat cancer announced today that its licensee, Changzhou Biotech (CBI), has been granted regula...
Read More
Company News February 26, 2024 Oxford Vacmedix Comments: 0

Oxford Vacmedix team support new University of Oxford educational initiative

The team at Oxford Vacmedix contribute to the design and the delivery of a novel MSc course in Applied Cancer Science being run by the Department of Oncology at the University of Oxford Oxford, UK – 26th February 2024 Press Release – Oxford Vacmedix support new University of Oxford educational initiative Oxford Vacmedix (OVM), the clinical stage company developing therapeutic cancer vaccines, announced today the involvement of the Management team in a brand new MSc course being run i...
Read More
Company News January 31, 2024 Oxford Vacmedix Comments: 0

Oxford Vacmedix announces major milestone in clinical development of OVM-200

OVM-200 Drug Product, manufactured to Good Manufacturing Process (GMP), has been certified stable three years post manufacture – a major milestone for OVM’s lead cancer vaccine, OVM-200 Oxford, UK – 31st January 2024 Press Release – OVM-200 major milestone three year stabilty Oxford Vacmedix (OVM), the clinical stage company developing therapeutic cancer vaccines, announced today that OVM-200 has been tested and independently certified as stable three years after manufacture. OVM...
Read More
Company News October 10, 2023 Oxford Vacmedix Comments: 0

New publication highlights importance of survivin as target and potential for combination use to treat cancer

A new publication in Advanced Therapeutics comprehensively reviews the rationale and preclinical results for OVM-200 both alone and in combination. Oxford, UK – 10th October 2023 Press Release – Importance of Survivin as a target and potential for combination use to treat cancer Oxford Vacmedix (OVM), the UK-based biopharma company focused on the development of vaccines to treat cancer announced today the publication of a key research paper on its lead cancer vaccine,  OVM-200. The...
Read More
Company News May 26, 2023 Oxford Vacmedix Comments: 0

Oxford Vacmedix feature in ‘Advancing Immunology’

Oxford Vacmedix to feature in ITN Business’ programme ‘Advancing Immunology’ – exploring the use of new technology to develop vaccines to treat cancer Oxford, UK – 26th May 2023 ITN Business present Oxford Vacmedix in a new series on ‘Advancing Immunology’. The programme explores how cancer therapeutic vaccines are being trialled and could reduce the need for invasive treatments such as chemotherapy and radiotherapy for some cancers in future. Watch Oxfo...
Read More
Company News April 5, 2023 Oxford Vacmedix Comments: 0

Oxford Vacmedix sponsors MRC i-Case studentship at University of Oxford

New appointment In Professor Shisong Jiang’s research group in the Department of Oncology brings further expertise to research applications for Recombinant Overlapping Peptides (ROPs) Oxford, UK – 5th April 2023 Press Release – Oxford Vacmedix sponsors MRC i-Case studentship at University of Oxford Oxford Vacmedix (OVM), the UK-based biopharma company focused on the development of therapeutic cancer vaccines, announced today the award of an MRC i-Case studentship to fund a new D.Ph...
Read More
Company News September 8, 2022 Oxford Vacmedix Comments: 0

OVM-200 Phase 1 Clinical Trial featured on TV

The OVM-200 Phase 1 Clinical Trial at The Christie in Manchester was featured on ITV’s Granada News on Wednesday 7th September 2022. It is a first-in-class of ROP cancer vaccine in human clinical trial. ROP therapeutic vaccines will provide additional options for the treatment of cancer patients. Professor Shisong Jiang, Chief Scientific Officer and Founder of OVM said: We see the potential benefits of a vaccination approach both in stimulating the body’s immune system to attack the...
Read More
Publications
June 22, 2022 Oxford Vacmedix Comments: 0

In Vitro and In Vivo Antigen Presentation and Diagnosis Development of Recombinant Overlapping Peptides Corresponding to Mtb ESAT-6/CFP-10

The following publication describes a study developing the ROP-TB antigen for both in vitro IGRA-based TB diagnosis, as well as the in vivo skin test for TB diagnosis in both humans and cattle.  The advantages of the ROP-TB diagnosis are firstly distinguishing Mtb infection from BCG vaccination, and secondly, being suitable for industrial manufacture. Read the full article: ROP-TB Diagnosis By Qing Zhang, Xiong Lu, Liang Gao, Siyu Tao, Yinghua Ge, Daocheng Cui, Renying Zhu, Wenshu Lu, Jian Wang...
Read More
Company News May 23, 2022 Oxford Vacmedix Comments: 0

Oxford Vacmedix founder Dr Shisong Jiang invited to Buckingham Place

Dr Shisong Jiang recieved an invitation to the annual Royal Garden Party to recognise many years’ service to charity. Oxford, 23rd May 2022 Press Release – Dr Shisong Jiang invited to Buckingham Palace On Wednesday 18 May, the Dr Shisong Jiang, the founder and CSO of Oxford Vacmedix, was invited to Buckingham Palace in London for the Royal Garden Party, an annual event that invites a broad range of people – all of whom have made a positive impact in their community – to be re...
Read More
en_GBEnglish
en_GBEnglish